

# Resource Summary Report

Generated by [dkNET](#) on Sep 4, 2026

## SJ-GBM2

RRID:CVCL\_M141

Type: Cell Line

---

### Proper Citation

RRID:CVCL\_M141

---

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_M141](https://web.expasy.org/cellosaurus/CVCL_M141)

**Proper Citation:** RRID:CVCL\_M141

**Description:** Cell line SJ-GBM2 is a Cancer cell line with a species of origin Homo sapiens (Human)

**Sex:** Female

**Disease:** Glioblastoma

**Defining Citation:** [PMID:7634381](#), [PMID:9220028](#), [PMID:9802058](#), [PMID:10402232](#), [PMID:10933967](#), [PMID:11306486](#), [PMID:20922763](#)

**Comments:** Population: Caucasian., Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel.

**Category:** Cancer cell line

**Organism:** Homo sapiens (Human)

**Name:** SJ-GBM2

**Synonyms:** SJ-GBM-2, SJGBM2, SJ-G2, SJG2

**Cross References:** BTO:BTO\_0006332, cancercellines:CVCL\_M141, IARC\_TP53:24985, Wikidata:Q54953524

**ID:** CVCL\_M141

**Record Creation Time:** 20220427T221543+0000

**Record Last Update:** 20260904T015654+0000

---

### Ratings and Alerts

No rating or validation information has been found for SJ-GBM2.

No alerts have been found for SJ-GBM2.

---

## Data and Source Information

**Source:** [Cellosaurus](#)

---

## Usage and Citation Metrics

We found 7 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [dkNET](#) .

Kolodziejczak AS, et al. (2026) Preclinical drug screen identifies WEE1 inhibitor and vinca alkaloid as a combination treatment concept for Li-Fraumeni syndrome medulloblastoma. *iScience*, 29(2), 114564.

Loboda A, et al. (2026) Integration and validation of complementary ex vivo assays for functional precision oncology. *NPJ precision oncology*, 10(1).

Febres-Aldana CA, et al. (2025) Pan-Cancer Analysis of Oncogenic MET Fusions Reveals Distinct Pathogenomic Subsets with Differential Sensitivity to MET-Targeted Therapy. *Cancer discovery*, 15(6), 1141.

Jane EP, et al. (2023) Targeting mitochondrial energetics reverses panobinostat- and marizomib-induced resistance in pediatric and adult high-grade gliomas. *Molecular oncology*, 17(9), 1821.

Mota M, et al. (2023) Targeting SWI/SNF ATPases in H3.3K27M diffuse intrinsic pontine gliomas. *Proceedings of the National Academy of Sciences of the United States of America*, 120(18), e2221175120.

Sanders LM, et al. (2020) Identification of a differentiation stall in epithelial mesenchymal transition in histone H3-mutant diffuse midline glioma. *GigaScience*, 9(12).

Chung C, et al. (2020) Integrated Metabolic and Epigenomic Reprograming by H3K27M Mutations in Diffuse Intrinsic Pontine Gliomas. *Cancer cell*, 38(3), 334.